EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
about
Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical RelevanceEpidemiology of Lung Cancer in Korea: Recent TrendsClinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.State of Art of Cancer Pharmacogenomics in Latin American Populations.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerThe prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisSuccesses and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cellsComparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Leveraging Genomic Factors to Improve Benefit-Risk.Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system.Biology and clinical significance of circulating tumor cell subpopulations in lung cancerSelection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase InhibitorsThe "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.Characterizing the last holdouts.EGFR targeted therapy in lung cancer; an evolving storyEGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma.Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma.Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer.Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001.Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.
P2860
Q26750970-93C0AD08-DC7C-4B69-8489-3166F640F414Q28077423-294679A6-DA9B-4679-A805-F3928F2F32A7Q33779181-B969A511-7284-4C6C-8F10-E02663FBA82FQ33798605-C4362B8F-2BB2-4D75-ADAB-73A42714ABF4Q33838298-08CB55AA-DD34-4CCA-B623-8AF355291DD2Q36096398-51CE0E2E-2966-48AF-9E24-F0D8AE6C6988Q36163279-933CE95E-B1B2-4B70-950F-34292499E70FQ36305457-468E3F70-EA60-42D1-8CDA-8D7C37AF2235Q37589825-EF392261-1C04-4801-A919-2A33C6980C5AQ37644815-1623B041-05C6-4ABA-8B4B-E87E1A640F75Q37706099-4D182A3D-86F8-4785-8829-90BD0E995FABQ37708018-526E79D6-B35E-4984-AEEA-E2E42F70D5B2Q37716487-085CE4F5-E897-4107-B426-B8FE83577C50Q37726138-4585D6B3-8445-4FBA-A014-3132469087BBQ37735770-18D48FFE-8A92-4D4C-8D4B-07BA66317C15Q37741998-1D4039A1-B246-450A-A744-CFB104A38DCAQ37742623-1CFE15CA-F203-4E58-9E6E-8D21E4E32400Q38719689-B16388C0-08B0-430F-86C5-2E47C11614EEQ38767492-4406F4F0-A7E1-410E-9233-FF8BC0303828Q41507784-CDF33B19-0403-4770-9F9D-E030FF32683AQ41605032-2CF06CC5-E414-4C9C-9380-92C878A25FE8Q41678123-CFD99CFD-CE8E-41AE-A465-A6FFBC775025Q42283950-98E07956-89B8-4B41-930C-8980A5DB3893Q42315769-70D58CCA-4D29-4ECB-A39D-FDC76DD068DEQ42322394-A91F0CC9-89A3-4175-802F-2F4010F5D44EQ42731684-6653B46A-7924-4FEE-990D-3D7BCF0DAD7DQ45719513-9316900C-E1D7-4AE2-A096-3B3C4EB45C83Q47106968-FCD5D72A-0669-4ED5-93F4-082C53DB85CCQ47133535-412C033F-BE02-4F70-8F7F-3EF3878B65FAQ47145084-C241B181-6084-4C39-A3BB-4128EC3D487BQ47574237-CC198DDB-DD7F-4EA4-9111-337B39F121CDQ47654457-015813EA-E477-49A8-88EF-3D8F41CD4598Q47898300-EF6623A5-A97C-4CA8-B8C4-CA64858E7474Q47939444-16893C91-A6E2-44FB-85C1-F9DE1DB476A3Q49434203-4F1A2BE1-05FE-4189-9138-EA32AE8D9526Q49980448-219329DC-EF9F-4679-A0D0-1634E88A6336Q50218607-BD4357CC-89E3-487A-B836-B73844969C14Q51760971-EABE8E2C-12AD-43E4-B9F0-AAC8D10B5EFBQ52318443-B40F3084-E5FB-41D9-8D32-4D003127E366Q52332839-3D50B945-F5BF-4591-9DF6-D05D8E5CAA5B
P2860
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@ast
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@en
type
label
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@ast
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@en
prefLabel
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@ast
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@en
P2093
P2860
P1476
EGFR mutation incidence in non ...... l map by ethnicity (mutMapII).
@en
P2093
Anita Midha
Rose McCormack
Simon Dearden
P2860
P304
P577
2015-08-15T00:00:00Z